Skip to main content
Livermore
Livermore
ZHEN

Amylyx Pharmaceuticals, Inc.

AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001658551

In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Amylyx Pharmaceuticals, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of AMLX: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders072+72
Shares023.4M+23.4M
Value$0$299.9M+$299.9M

New holders (72)

Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to AMLX in Q1 2022
InstitutionSharesValue% of portfolio
Viking Global Investors LPSuperinvestorViking Global Investors7,170,536$92.1M0.37%
Bain Capital Life Sciences Investors, LLC2,756,050$35.4M3.44%
Boxer Capital, LLC2,200,000$28.3M1.45%
Perceptive Advisors LLC1,474,107$18.9M0.39%
Rock Springs Capital Management LP998,307$12.8M0.32%
Vanguard Group Inc992,188$12.8M0.00%
Verition Fund Management LLC925,353$11.9M0.23%
Tybourne Capital Management (HK) Ltd768,603$9.88M0.58%
Falcon Edge Capital, LP617,220$7.93M0.71%
683 Capital Management, LLC677,714$7.68M0.45%
Marshall Wace, LLP584,464$7.51M0.02%
BlackRock Inc.572,341$7.35M0.00%
Citadel Advisors LLC501,636$6.45M0.01%
Allspring Global Investments Holdings, LLC402,324$5.17M0.01%
Ikarian Capital, LLC396,654$5.10M1.55%
Woodline Partners LP390,229$5.01M0.08%
Geode Capital Management, LLC190,150$2.44M0.00%
Agf Investments Inc.160,000$2.06M0.02%
Renaissance Technologies LLC146,400$1.88M0.00%
Millennium Management LLC137,241$1.76M0.00%
Sofinnova Investments, Inc.100,000$1.28M0.11%
State Street Corp99,212$1.27M0.00%
Wells Fargo & Company89,824$1.16M0.00%
FMR LLC88,125$1.13M0.00%
Ameriprise Financial Inc82,310$1.06M0.00%
Northern Trust Corp82,170$1.06M0.00%
Artal Group S.A.75,000$964.0K0.04%
Charles Schwab Investment Management Inc73,027$939.0K0.00%
Balyasny Asset Management LLC62,915$808.0K0.00%
Oasis Management Co Ltd.50,000$643.0K0.11%
Boothbay Fund Management, LLC48,271$620.0K0.02%
Susquehanna International Group, LLP46,565$598.0K0.00%
Morgan Stanley42,345$544.0K0.00%
PFS Investments Inc.39,558$508.0K0.01%
Adage Capital Partners GP, L.L.C.37,200$478.0K0.00%
Caption Management, LLC36,667$472.0K0.03%
Atom Investors LP36,691$471.0K0.22%
Cubist Systematic Strategies, LLC34,914$449.0K0.00%
Silverarc Capital Management, LLC30,000$386.0K0.21%
Jane Street Group, LLC29,246$376.0K0.00%
Walleye Capital LLC28,187$362.0K0.01%
Bank of New York Mellon Corp26,451$340.0K0.00%
Caas Capital Management LP17,000$218.0K0.04%
Squarepoint Ops LLC15,000$193.0K0.00%
Nuveen Asset Management, LLC13,230$170.0K0.00%
Pura Vida Investments, LLC10,000$129.0K0.02%
MetLife Investment Management6,785$87.2K0.00%
Deutsche Bank AG5,349$69.0K0.00%
Simplex Trading, LLC5,198$66.0K0.00%
American International Group, Inc.4,760$61.0K0.00%
JPMorgan Chase & Co4,497$58.0K0.00%
Royal Bank of Canada4,294$56.0K0.00%
California State Teachers Retirement System4,086$53.0K0.00%
UBS Group AG4,157$53.0K0.00%
New York State Common Retirement Fund4,000$51.0K0.00%
Bank of America Corp2,904$38.0K0.00%
STRS Ohio2,300$29.0K0.00%
Quantbot Technologies LP2,200$28.0K0.00%
Amalgamated Bank1,763$23.0K0.00%
Amalgamated Financial Corp.1,763$23.0K0.00%
Barclays PLC1,559$20.0K0.00%
Advisor Group Holdings, Inc.1,400$18.0K0.00%
Group One Trading, L.P.1,243$16.0K0.00%
Citigroup Inc1,154$15.0K0.00%
Point72 Hong Kong Ltd1,159$15.0K0.00%
Steward Partners Investment Advisory, LLC1,100$14.0K0.00%
Legal & General Group Plc905$12.0K0.00%
Metropolitan Life Insurance Co795$10.2K0.00%
Ameritas Investment Partners, Inc.744$10.0K0.00%
Tower Research Capital LLC (TRC)711$10.0K0.00%
High Net Worth Advisory Group LLC500$6.00K0.00%
Northwestern Mutual Wealth Management Co300$4.00K0.00%

Sold out (0)

Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.

None.